Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
International Journal of Hematology
Published in: International Journal of Hematology 5/2007

01-12-2007 | Letter to the Editor

Encouraging Results of Low-Dose Etoposide in the Treatment of Early-Onset Hemophagocytic Syndrome Following Allogeneic Hematopoietic Stem Cell Transplantation

Authors: Maho Koyama, Akihisa Sawada, Masahiro Yasui, Masami Inoue, Keisei Kawa

Published in: International Journal of Hematology | Issue 5/2007

Login to get access
Metadata
Title
Encouraging Results of Low-Dose Etoposide in the Treatment of Early-Onset Hemophagocytic Syndrome Following Allogeneic Hematopoietic Stem Cell Transplantation
Authors
Maho Koyama
Akihisa Sawada
Masahiro Yasui
Masami Inoue
Keisei Kawa
Publication date
01-12-2007
Publisher
Springer Japan
Published in
International Journal of Hematology / Issue 5/2007
Print ISSN: 0925-5710
Electronic ISSN: 1865-3774
DOI
https://doi.org/10.1007/BF02984009

Other articles of this Issue 5/2007

International Journal of Hematology 5/2007 Go to the issue

OriginalPaper

Risk factors of venous thromboembolism in Thai patients

Case Report

Wilms Tumor gene WT1 peptide-based immunotherapy induced a minimal response in a patient with advanced therapy-resistant multiple myeloma

Case Report

Feasibility and obstacles in home chemotherapy for malignant lymphoma

Letter to the Editor

Quantitative assessment of elevated D-dimers

OriginalPaper

Treatment of streptozotocin-induced diabetes mellitus in mice by intra—bone marrow bone marrow transplantation plus portal vein injection of β cells induced from bone marrow cells

Letter to the Editor

Breast cancer and chronic myeloid leukemia: A short review
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits